《2021年心房颤动患者非维生素K拮抗剂口服抗凝药物应用实践指南》解读  

Interpretation of 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

作　　者：李海涛[1] 吴明[1] LI Haitao;WU Ming(Department of Cardiology,Hainan General Hospital,Hainan Affiliated Hospital of Hainan Medical University,Haikou 570311,China)

机构地区：[1]海南省人民医院(海南医学院附属海南医院)心内科,海口570311

出　　处：《心电与循环》2022年第5期421-424,共4页Journal of Electrocardiology and Circulation

基　　金：海南省基础与应用基础研究计划(2019RC368)。

摘　　要：欧洲心律协会(EHRA)发布的《2021年心房颤动(下称房颤)患者非维生素K拮抗剂口服抗凝药物(NOAC)应用实践指南》(下称《2021年指南》)是目前关于NOAC应用最为全面的临床指南。《2021年指南》对临床适应证、药代动力学监测、合并慢性疾病患者的管理、围术期管理、并发症处理及特殊人群剂量调整等各方面均作了详细描述及推荐,现就该指南的重点部分及主要观点作一解读。The"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation"issued by EHRA is currently considered as the most comprehensive guideline on the clinical application of NOAC.The EHRA Practical Guide provide support for safe and effective use of NOAC in daily practice by focusing on the scientific evidence for eligibility and dosing,follow-up procedure,management of patients with chronic disease or in perioperative period,application in particular patients and management of complications,thereby we interpreted its key parts for practitioners.

关 键 词：心房颤动 非维生素 K拮抗剂口服抗凝药物 欧洲心律协会 指南 

分 类 号：R541.75[医药卫生—心血管疾病]